Research Explorer

Your browser does not support JavaScript or JavaScript is not enabled. Without JavaScript some functions of this webapplication may be disabled or cause error messages. To enable JavaScript, please consult the manual of your browser or contact your system administrator.

Researcher

Irina Lambertz

Awards & Distinctions

36 Results

2021

Microbes exploit death-induced nutrient release by gut epithelial cells

Christopher AndersonChristopher B. MedinaBrady J. BarronLaura KarvelyteTania Love AaesIrina LambertzJustin S. A. PerryParul MehrotraAmanda GonçalvesKelly Lemeire et al.

A1 Journal Article in NATURE

2020

The ETS transcription factor ETV5 is a target of activated ALK in neuroblastoma contributing to increased tumour aggressiveness

Liselot MusIrina LambertzShana ClaeysCandy KumpsWouter Van LoockeChristophe Van NesteGanesh UmapathyMarica VaapilChristoph BartenhagenGenevieve Laureys et al.

A1 Journal Article in SCIENTIFIC REPORTS

2018

Expressed repetitive elements are broadly applicable reference targets for normalization of reverse transcription-qPCR data in mice

Marjolijn RenardSuzanne VanhauwaertMarine VanhomwegenAli RihaniNiels VandammeSteven GoossensGeert BerxPieter Van VlierbergheJody J HaighBieke Decaesteker et al.

A1 Journal Article in SCIENTIFIC REPORTS

2017

HBP1 is a negative epigenetic regulator of MYCN-driven neuroblastoma through interaction with the PRC2 complex

Shana ClaeysGeertrui DeneckerIrina LambertzEls JanssensSuzanne VanhauwaertBieke DecaestekerTom Van MaerkenBram De WildeGenevieve LaureysKristina Althoff et al.

The ETV5 oncogene is a target of activated ALK signaling in neuroblastoma

Liselot MusIrina LambertzCandy KumpsShana ClaeysGeertrui DeneckerWouter Van LoockeChristophe Van NesteJan KosterRogier VersteegNadine Van Roy et al.

The ETV5 oncogene is a target of activated ALK signaling in neuroblastoma

Liselot MusIrina LambertzCandy KumpsShana ClaeysGeertrui DeneckerWouter Van LoockeChristophe Van NesteJan KosterRogier VersteegNadine Van Roy et al.

The ETV5 oncogene is a target of activated ALK signaling in neuroblastoma

Liselot MusIrina LambertzCandy KumpsShana ClaeysGeertrui DeneckerWouter Van LoockeChristophe Van NesteJan KosterRogier VersteegNadine Van Roy et al.

The HBP1 tumor suppressor is a negative epigenetic regulator of MYCN driven neuroblastoma through interaction with the PRC2 complex

Geertrui DeneckerShana ClaeysIrina LambertzEls JanssensSuzanne VanhauwaertBieke DecaestekerTom Van MaerkenBram De WildeGenevieve LaureysKristina Althoff et al.

The HBP1 tumour suppressor is a negative epigenetic regulator of MYCN-driven neuroblastoma through interaction with the PRC2 complex

Shana ClaeysGeertrui DeneckerBieke DecaestekerEls JanssensCandy KumpsSara De BrouwerIrina LambertzAnnelies FieuwSuzanne VanhauwaertKristina Althoff et al.

2016

Dual targeting of ALK and RET: establishing a novel basis for the treatment of neuroblastoma

Liselot MusShana ClaeysBram De WildeGenevieve LaureysAlan Van GoethemJohannes SchulteKatleen De PreterIrina LambertzFranki Speleman

Dual targeting of ALK and RET: establishing a novel basis for the treatment of neuroblastoma

Liselot MusShana ClaeysBram De WildeGenevieve LaureysAlan Van GoethemJohannes SchulteKatleen De PreterIrina LambertzFranki Speleman

ETV5 functionally connect ALK and CXCR4 signaling in neuroblastoma

Irina LambertzShana ClaeysCandy KumpsLiselot MusEls JanssensNadine Van RoyBram De WildeGenevieve LaureysJan CoolsOlivier De Wever et al.

ETV5 functionally connects ALK and CXCR4 signaling in neuroblastoma

Irina LambertzLiselot MusCandy KumpsShana ClaeysNadine Van RoyBram De WildeGenevieve LaureysJohannes ShulteOlivier De WeverKatleen De Preter et al.

Sensing mutant ALK: Capicua and ETV5 as executors of aberrant ALK-driven MAPK signaling

Irina LambertzLiselot MusCandy KumpsShana ClaeysWouter Van LoockeChristophe Van NesteJan KosterRogier VersteegNadine Van RoyBram De Wilde et al.

The HBP1 tumor suppressor is a negative epigenetic regulator of MYCN driven neuroblastoma through interaction with the PRC2 complex

Shana ClaeysIrina LambertzEls JanssensSuzanne VanhauwaertBieke DecaestekerCandy KumpsSara De BrouwerAnnelies FieuwTom Van MaerkenBram De Wilde et al.

The HBP1 tumor suppressor is a negative epigenetic regulator of MYCN driven neuroblastoma through interaction with the PRC2 complex

Shana ClaeysIrina LambertzEls JanssensSuzanne VanhauwaertBieke DecaestekerCandy KumpsSara De BrouwerAnnelies FieuwTom Van MaerkenBram De Wilde et al.

The HBP1 tumor suppressor is an epigenetic regulator of MYCN driven neuroblastoma through interaction with the PRC2 complex

Shana ClaeysIrina LambertzAlan Van GoethemCandy KumpsSara De BrouwerAnnelies FieuwTom Van MaerkenKristina AlthoffJohannes SchulteJean-Baptiste Demoulin et al.

2015

ETV5 functionally connect ALK and RET signaling in neuroblastoma

Irina LambertzShana ClaeysCandy KumpsLiselot MusAnneleen BeckersEls JanssensNadine Van RoyGenevieve LaureysJohannes SchulteOlivier De Wever et al.

HBP1 downregulation through mutant ALK represents a novel mechanism for cooperative MYCN activation in neuroblastoma

Shana ClaeysIrina LambertzAlan Van GoethemCandy KumpsSara De BrouwerAnnelies FieuwTom Van MaerkenKristina AlthoffJohannes SchulteJean-Baptiste Demoulin et al.

Synergistic combined molecular treatment targeting the HBP1 tumor suppressor gene in neuroblastoma

Shana ClaeysIrina LambertzAlan Van GoethemAnneleen BeckersCandy KumpsTom Van MaerkenJohannes SchulteKatleen De PreterFranki Speleman

The HBP1 tumour suppressor at multiple regulatory cross roads in neuroblastoma

Shana ClaeysIrina LambertzAlan Van GoethemAnneleen BeckersCandy KumpsTom Van MaerkenJohannes SchulteKatleen De PreterFranki Speleman

Upregulation of MAPK negative feedback regulators and RET in mutant ALK neuroblastoma : implications for targeted treatment

Irina LambertzCandy KumpsShana ClaeysSven LindnerAnneleen BeckersEls JanssensDaniel CarterAlex CazesBelamy CheungMarilena De Mariano et al.

Upregulation of MAPK negative feedback regulators and RET in mutant ALK neuroblastoma : implications for targeted treatment

Irina LambertzCandy KumpsShana ClaeysSven LindnerAnneleen BeckersEls JanssensDaniel R CarterAlex CazesBelamy B CheungMarilena De Mariano et al.

A1 Journal Article in CLINICAL CANCER RESEARCH

Upregulation of MAPK negative feedback regulators and RET in mutant ALK neuroblastoma : implications for targeted treatment

Irina LambertzCandy KumpsShana ClaeysSven LindnerAnneleen BeckersEls JanssensDaniel CarterAlex CazesBelamy CheungMarilena De Mariano et al.

Upregulation of MAPK negative feedback regulators and RET in mutant ALK neuroblastoma : implications for targeted treatment

Irina LambertzCandy KumpsShana ClaeysSven LindnerAnneleen BeckersEls JanssensDaniel CarterAlex CazesBelamy CheungMarilena De Mariano et al.

2014

Characterization of ALK driven molecular networks identifies perturbed RET and cholinergic signaling in neuroblastoma

Irina LambertzCandy KumpsShana ClaeysSven LindlerAnneleen BeckersEls JanssensMarilena De MarianoSara De BrouwerJay GibbonsGenevieve Laureys et al.

The HBP1 tumor suppressor is a druggable ALK downregulated gene controlling MYCN activity

Shana ClaeysCandy KumpsIrina LambertzSara De BrouwerSven LindnerAlan Van GoethemTom Van MaerkenJorge VialardJan CoolsJohannes Schulte et al.

The HBP1 tumor suppressor is a druggable ALK downregulated gene controlling MYCN activity

Shana ClaeysCandy KumpsIrina LambertzSara De BrouwerSven LindnerAlan Van GoethemTom Van MaerkenJorge VialardJan CoolsJohannes Schulte et al.

2013

The need for transparency and good practices in the qPCR literature

Stephen A BustinVladimir BenesJeremy GarsonJan HellemansJim HuggettMikael KubistaReinhold MuellerTania NolanMichael W PfafflGregory Shipley et al.

A1 Journal Article in NATURE METHODS

2012

Dickkopf-3 is regulated by the MYCN-induced miR-17-92 cluster in neuroblastoma

Sara De BrouwerPieter MestdaghIrina LambertzFilip PattynAnne De PaepeFrank WestermannChristina SchroederJohannes H SchulteAlexander SchrammKatleen De Preter et al.

A1 Journal Article in INTERNATIONAL JOURNAL OF CANCER

Synthetic lethality between Rb, p53 and Dicer or miR-17-92 in retinal progenitors suppresses retinoblastoma formation

David NittnerIrina LambertzFrederic ClermontPieter MestdaghCorinna KöhlerSøren Jensby NielsenAart JochemsenFranki SpelemanJo VandesompeleMichael A Dyer et al.

A1 Journal Article in NATURE CELL BIOLOGY

2011

MicroRNA control of cancer development

Irina LambertzJean-Christophe Marine

2010

An illegitimate microRNA target site within the 3' UTR of MDM4 affects ovarian cancer progression and chemosensitivity

Jessica WynendaeleAnja BöhnkeEleonora LeucciSøren Jensby NielsenIrina LambertzStefanie HammerNadja SbrzesnyDana KubitzaAnja WolfElise Gradhand et al.

A1 Journal Article in CANCER RESEARCH

Monoallelic but not biallelic loss of Dicer1 promotes tumorigenesis in vivo

Irina LambertzDavid NittnerPieter MestdaghGeertrui DeneckerJo VandesompeleMA DyerJean-Christophe Marine

A1 Journal Article in CELL DEATH AND DIFFERENTIATION

2009

Antitumor Activity of the Selective MDM2 Antagonist Nutlin-3 Against Chemoresistant Neuroblastoma With Wild-Type p53

Tom Van MaerkenLiesbeth FerdinandeJasmien TaildemanIrina LambertzNurten YigitLiesbeth VercruysseAli RihaniMartin MichaelisJindrich CinatlClaude Cuvelier et al.

A1 Journal Article in JOURNAL OF THE NATIONAL CANCER INSTITUTE

2006

Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma

Tom Van MaerkenFranki SpelemanJ VERMEULENIrina LambertzSarah De ClercqEls De SmetNurten YigitV COPPENSJan PhilippéAnne De Paepe et al.

A1 Journal Article in CANCER RESEARCH